查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771627

病毒疫苗CDMO市場規模、佔有率、趨勢分析報告：按類型、服務、工作流程、最終用途、地區、細分市場預測，2025-2033年

Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

病毒疫苗CDMO市場摘要

2024 年全球病毒疫苗 CDMO 市場規模估計為 22.3 億美元，預計到 2033 年將達到 73.9 億美元，2025 年至 2033 年的複合年成長率為 15.1%。市場成長主要得益於感染疾病爆發導致的病毒疫苗合約製造需求不斷成長、基於病毒載體的預防和治療平台的採用日益廣泛以及對快速可擴展製造外包解決方案的需求。

此外，流感、人類乳突病毒 (HPV) 和肝炎等病毒性疾病的日益流行，以及登革熱、呼吸道合胞病毒和病毒性出血熱等新興威脅，迫使公共和私營疫苗開發商加快生產進度。去活化和重組病毒疫苗需要高水準的生物安全、品質和製程控制，這促使製藥公司轉向擁有成熟病毒平台、BSL-2/3 防護基礎設施和端到端合規能力的合約開發生產組織 (CDMO)。此外，自新冠疫情爆發以來，各國政府和國際衛生組織大幅增加了用於疫情防治的資金和長期採購契約，這增加了對可擴展病毒疫苗生產的需求。透過提供病毒種子庫、細胞株開發、載體工程和 cGMP 級病毒生產方面的專業知識，CDMO 正在幫助疫苗創新者加快開發速度，並在低營運風險的情況下實現監管里程碑。

一次性生物反應器、模組化無塵室以及包括預填充式注射器和凍乾管瓶在內的高速灌裝生產線的日益普及，使得外包成為小型生物技術公司和大型疫苗公司均能有效選擇的解決方案。此外，隨著眾多開發商尋求進軍新興市場，擁有分散式生產佈局並符合美國FDA、EMA和WHO PQ等多項區域性法規的CDMO（合約研發生產與製造）正成為商業供應協議的首選。此外，病毒載體技術在基因治療和腫瘤學領域的興起，正在模糊傳統疫苗和治療平台之間的界限，從而推動了對病毒CDMO服務的跨應用需求。隨著生技藥品的個人化和技術複雜性日益提升，龍沙、富士迪奧辛、三星生物和藥明生物等公司正在拓展其在上游病毒生產和下游無菌灌裝生產方面的能力，力求成為全球病毒疫苗開發新時代的戰略生產合作夥伴。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術格局
  • 定價模式分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章病毒疫苗CDMO市場：類型評估與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：類型變化分析
  • 按類型，2021-2033年
  • 減毒疫苗
  • 去活化疫苗
  • DNA疫苗
  • 次單位疫苗

第5章病毒疫苗CDMO市場：服務估算與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：服務波動分析
  • 按服務分類，2021-2033 年
  • 配方和工藝開發
    • 上游開發
    • 下游開發
  • 分析測試
  • 灌裝和精加工服務
  • 包裝和標籤
  • 其他

6. 病毒疫苗CDMO市場：工作流程估算與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：工作流程變化分析
  • 按工作流程，2021-2033 年
  • 臨床
  • 商業的

7. 病毒疫苗CDMO市場：最終用途預估與趨勢分析

  • 細分儀表板
  • 病毒疫苗 CDMO 市場：最終用途差異分析
  • 依最終用途，2021-2033 年
  • 生物製藥公司
  • 學術研究所
  • 其他

第8章區域業務分析

  • 區域儀表板
  • 按地區，2021-2033年
  • 北美洲
    • 2021-2033年北美病毒疫苗CDMO市場預測及預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲病毒疫苗CDMO市場預測及預測
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太病毒疫苗CDMO市場預測及預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2021-2033年拉丁美洲病毒疫苗CDMO市場預測及預測
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2021-2033年中東及非洲病毒疫苗CDMO市場預測及預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 公司分類
    • 市場領導者
    • 新興企業
  • Company Market Assessment Analysis, 2024
  • 公司簡介
    • Lonza
    • Catalent Pharma
    • Thermo Fisher Scientific
    • Samsung Biologics
    • Fujifilm Diosynth Biotechnologies
    • WuXi Biologics
    • Recipharm AB.
    • HALIX BV
    • Batavia Biosciences BV
    • Alcami Corporation
Product Code: GVR-4-68040-624-6

Viral Vaccines CDMO Market Summary

The global viral vaccines CDMO market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 7.39 billion by 2033, growing at a CAGR of 15.1% from 2025 to 2033. The growth of the market is mainly due rising demand for outsourced manufacturing of viral vaccines, driven by increased prevalence of infectious diseases, growing adoption of viral vector-based platforms for both prophylactic and therapeutic use, and the need for rapid, scalable production solutions.

Furthermore,the increasing prevalence of viral illnesses such as influenza, human papillomavirus (HPV), hepatitis, and emerging threats like dengue, RSV, and viral hemorrhagic fevers has pushed public and private vaccine developers to accelerate production timelines. Given the high biosafety, quality, and process control requirements associated with live-attenuated, inactivated, and recombinant viral vaccines, pharmaceutical companies are increasingly turning to CDMOs with established viral platforms, BSL-2/3 containment infrastructure, and end-to-end compliance capabilities. Moreover, post-COVID-19, governments and global health agencies have significantly increased funding and long-term procurement agreements for pandemic preparedness, which has increased demand for scalable viral vaccine production. CDMOs offer specialized knowledge in viral seed banking, cell line development, vector engineering, and cGMP-grade virus production, enabling vaccine innovators to shorten development timelines and meet regulatory milestones with lower operational risk.

The growing adoption of single-use bioreactors, modular cleanrooms, and high-speed fill-finish lines including prefilled syringes and lyophilized vials has made outsourcing an efficient alternative for both small biotech firms and large vaccine players. Additionally, as several developers seek to expand into global markets, CDMOs with multi-regional regulatory compliance such as U.S. FDA, EMA, WHO PQ and distributed manufacturing footprints are favored for commercial supply contracts. Further, the rise of viral vector technologies in gene therapy and oncology has also unclear the lines between traditional vaccines and therapeutic platforms, increasing cross-application demand for viral CDMO services. As biologics become more personalized and technically complex, companies like Lonza, Fujifilm Diosynth, Samsung Biologics, and WuXi Biologics are scaling both upstream viral production and downstream sterile fill-finish capacities, positioning themselves as strategic manufacturing partners in the next era of global viral vaccine development.

Global Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2033. For this study, Grand View Research has segmented the global viral vaccines CDMO market report based on type, workflow, service, end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Attenuated Vaccine
  • Inactivated Vaccine
  • DNA Vaccines
  • Subunit Vaccines
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Formulation & Process Development
    • Upstream Development
    • Downstream Development
  • Analytical Testing
  • Fill-Finish Services
  • Packaging & Labeling
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral Vaccines CDMO Market; Type Movement Analysis
  • 4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • 4.4. Attenuated Vaccine
    • 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inactivated Vaccine
    • 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. DNA Vaccines
    • 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Subunit Vaccines
    • 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral Vaccines CDMO Market; Service Movement Analysis
  • 5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 5.4. Formulation & Process Development
    • 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Upstream Development
      • 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Downstream Development
      • 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Analytical Testing
    • 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Fill-Finish Services
    • 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Packaging & Labeling
    • 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
  • 6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • 6.4. Clinical
    • 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Commercial
    • 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
  • 7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • 7.4. Biopharmaceutical Companies
    • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic and Research Institutes
    • 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Regional Dashboard
  • 8.2. Global Viral Vaccines CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • 8.3. North America
    • 8.3.1. North America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. U.S. Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Canada Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Mexico Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Germany Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. UK
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. UK Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. France Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Italy Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Spain Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Denmark Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Sweden Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Competitive Scenario
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Norway Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Japan Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. China Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. India Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. South Korea Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Australia
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Australia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Thailand
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Thailand Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Brazil Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Argentina Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. South Africa Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Saudi Arabia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. UAE Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Kuwait Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Company Market Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Lonza
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Catalent Pharma
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Thermo Fisher Scientific
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Samsung Biologics
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Fujifilm Diosynth Biotechnologies
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. WuXi Biologics
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Recipharm AB.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. HALIX B.V
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Batavia Biosciences B.V
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Alcami Corporation
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America viral vaccines CDMO market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 3 North America viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 4 North America viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 5 North America viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 6 North America viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 8 U.S. viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 9 U.S. viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 10 U.S. viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 11 U.S. viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 12 Canada viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 13 Canada viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 14 Canada viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 15 Canada viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 16 Mexico viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 17 Mexico viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 18 Mexico viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 19 Mexico viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 20 Europe viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 21 Europe viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 22 Europe viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 23 Europe viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 24 Europe viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 25 UK viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 26 UK viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 27 UK viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 28 UK viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 29 Germany viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 30 Germany viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 31 Germany viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 32 Germany viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 33 France viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 34 France viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 35 France viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 36 France viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 37 Italy viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 38 Italy viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 39 Italy viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 40 Italy viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 41 Spain viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 42 Spain viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 43 Spain viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 44 Spain viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 45 Denmark viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 46 Denmark viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 47 Denmark viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 48 Denmark viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 49 Sweden viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 50 Sweden viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 51 Sweden viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 52 Sweden viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 53 Norway viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 54 Norway viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 55 Norway viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 56 Norway viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 62 Japan viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 63 Japan viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 64 Japan viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 65 Japan viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 66 China viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 67 China viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 68 China viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 69 China viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 70 India viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 71 India viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 72 India viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 73 India viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 74 Australia viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 75 Australia viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 76 Australia viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 77 Australia viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Korea viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 79 South Korea viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 80 South Korea viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 81 South Korea viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 82 Thailand viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 83 Thailand viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 84 Thailand viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 85 Thailand viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 86 Latin America viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 87 Latin America viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 88 Latin America viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 89 Latin America viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 90 Latin America viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 91 Brazil viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 92 Brazil viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 93 Brazil viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 94 Brazil viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 95 Argentina viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 96 Argentina viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 97 Argentina viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 98 Argentina viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 99 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 100 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 101 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 102 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 103 Middle East and Africa viral vaccines CDMO market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 104 South Africa viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 105 South Africa viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 106 South Africa viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 107 South Africa viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 112 UAE viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 113 UAE viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 114 UAE viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 115 UAE viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 116 Kuwait viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 117 Kuwait viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 118 Kuwait viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 119 Kuwait viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Viral vaccines CDMO market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Porter's five force analysis
  • Fig. 17 PESTEL analysis
  • Fig. 18 Viral vaccines CDMO Market: Type outlook key takeaways
  • Fig. 19 Viral vaccines CDMO Market: Type movement analysis
  • Fig. 20 Attenuated vaccine market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 DNA vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Subunit vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 viral vaccines CDMO Market: Services outlook key takeaways
  • Fig. 24 viral vaccines CDMO Market: Services movement analysis
  • Fig. 25 Formulation & process development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Upstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Downstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Analytical testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Fill-finish services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Packaging & labeling market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 viral vaccines CDMO Market: Workflow outlook key takeaways
  • Fig. 33 viral vaccines CDMO Market: Workflow movement analysis
  • Fig. 34 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Academic and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Regional marketplace outlook, 2024 & 2030 (USD Million)
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 North America viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 U.S. viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Mexico viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Europe viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 UK regulatory affairs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Germany viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 France viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Italy viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Spain viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Denmark viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Sweden viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Asia Pacific viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Japan viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 China viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 India viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 South Korea viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Latin America viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Argentina viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 MEA viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE viral vaccines CDMO market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait regulatory affairs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market participant categorization
  • Fig. 95 Precision medicine market share/assessment analysis, 2024
  • Fig. 96 Strategic framework